Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis
- PMID: 16539824
Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis
Abstract
Objective: Systemic inflammation, insulin resistance, and endothelial dysfunction have been implicated in the development of cardiovascular disease in rheumatoid arthritis (RA). Since insulin resistance can promote endothelial dysfunction and anti-TNF-alpha blockade yield a rapid improvement of endothelial function, we have sought to assess whether TNF-alpha blockade may also result in a reduction of insulin serum levels and improvement of insulin resistance in RA patients who require this therapy because of severe and refractory disease.
Methods: We recruited patients with RA seen over a period of 1 month at Hospital Xeral-Calde, Lugo, Spain, that were on treatment with anti-TNF-alpha monoclonal antibody-infliximab. Patients with diabetes mellitus or plasma glucose > 110 mg/dl were excluded. Fasting blood samples were taken for determination of plasma glucose and serum insulin levels immediately prior to and after infliximab infusion.
Results: Twenty-seven RA patients (21 women; mean age: 57.1 years; mean DAS28: 4.43) fulfilled the inclusion criteria. Dramatic reduction in the serum insulin levels and insulin/glucose index was observed following infliximab infusion. Also, a significant improvement of insulin resistance and insulin sensitivity was found.
Conclusion: Our study confirms a rapid beneficial effect of infliximab on insulin resistance and insulin sensitivity in RA patients treated periodically with this drug. It may support the long-term use of drugs that act blocking TNF-alpha function to reduce the mechanisms implicated in the development of atherosclerosis in patients with RA.
Comment in
-
Impact of long-term anti-TNF-alpha treatment on insulin resistance in patients with rheumatoid arthritis.Clin Exp Rheumatol. 2008 Jan-Feb;26(1):159-60; author reply 160. Clin Exp Rheumatol. 2008. PMID: 18328169 No abstract available.
Similar articles
-
Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.Clin Exp Rheumatol. 2006 Jul-Aug;24(4):373-9. Clin Exp Rheumatol. 2006. PMID: 16956426
-
Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.Ann N Y Acad Sci. 2010 Apr;1193:153-9. doi: 10.1111/j.1749-6632.2009.05287.x. Ann N Y Acad Sci. 2010. PMID: 20398022 Review.
-
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.Clin Exp Rheumatol. 2010 Jan-Feb;28(1):56-62. Clin Exp Rheumatol. 2010. PMID: 20346239
-
TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients.Clin Exp Rheumatol. 2012 Nov-Dec;30(6):850-5. Epub 2012 Dec 17. Clin Exp Rheumatol. 2012. PMID: 22765845
-
Do Tumor Necrosis Factor (TNF) Inhibitors Improve the Glycemic Control in Patients with Rheumatoid Arthritis and Concomitant Diabetes Mellitus?Am J Ther. 2017 May;24(3):e347-e350. doi: 10.1097/MJT.0000000000000297. Am J Ther. 2017. PMID: 26103543 Review.
Cited by
-
Inflammatory markers and bariatric surgery: a meta-analysis.Inflamm Res. 2012 Aug;61(8):789-807. doi: 10.1007/s00011-012-0473-3. Epub 2012 May 16. Inflamm Res. 2012. PMID: 22588278
-
Insulin Signaling in Arthritis.Front Immunol. 2021 Apr 30;12:672519. doi: 10.3389/fimmu.2021.672519. eCollection 2021. Front Immunol. 2021. PMID: 33995414 Free PMC article. Review.
-
Inflammation-Nature's Way to Efficiently Respond to All Types of Challenges: Implications for Understanding and Managing "the Epidemic" of Chronic Diseases.Front Med (Lausanne). 2018 Nov 27;5:316. doi: 10.3389/fmed.2018.00316. eCollection 2018. Front Med (Lausanne). 2018. PMID: 30538987 Free PMC article.
-
Regulation of Metabolic Disease-Associated Inflammation by Nutrient Sensors.Mediators Inflamm. 2018 Jul 4;2018:8261432. doi: 10.1155/2018/8261432. eCollection 2018. Mediators Inflamm. 2018. PMID: 30116154 Free PMC article. Review.
-
TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome.J Clin Endocrinol Metab. 2011 Jan;96(1):E146-50. doi: 10.1210/jc.2010-1170. Epub 2010 Nov 3. J Clin Endocrinol Metab. 2011. PMID: 21047923 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical